Previous 10 | Next 10 |
Under its 505(b)(2) pathway, the FDA approves Pfenex's (NYSEMKT: PFNX ) PF708, a biosimilar to Eli Lilly's (NYSE: LLY ) osteoporosis med Forteo (teriparatide injection), for certain patients at high risk of fracture. More news on: Pfenex Inc., Eli Lilly and Company, Healthcare stocks new...
Pfenex earns a $2.5M milestone payment from Alvogen for U.S. approval Comparative human factors study report expected to be submitted to FDA as early as the second half of October 2019 SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today th...
Gainers: electroCore (NASDAQ: ECOR ) +43% . Avaya Holdings (NYSE: AVYA ) +26% . RingCentral (NYSE: RNG ) +26% . Exela Technologies (NASDAQ: XELA ) +23% . YRC Worldwide (NASDAQ: YRCW ) +17% . Zosano Pharma Corporation (NASDAQ: ZSAN ) +16% . BroadVision (NASDAQ: BVSN ) +16% . Ch...
SAN DIEGO, Sept. 16, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced that Ee...
SAN DIEGO, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced that Ee...
SAN DIEGO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that it has earned an $11 million development milestone under its development and license agreement with Jazz Pharmaceuticals. The milestone is associated with process development activities for ...
SAN DIEGO, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the app...
Pfenex Inc. (PFNX) Q2 2019 Results Conference Call August 8, 2019 4:30 PM ET Company Participants Eef Schimmelpennink – President and Chief Executive Officer Susan Knudson – Chief Financial Officer Conference Call Participants Andy Hsieh – William Blair ...
Pfenex (NYSEMKT: PFNX ): Q2 GAAP EPS of -$0.24 beats by $0.07 . More news on: Pfenex Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX), a clinical-stage development and licensing biotechnology company focused on leveraging its Pfēnex Expression Technology® to improve protein therapies for unmet patient needs, today announced the appo...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractua...
NEW YORK, NY / ACCESSWIRE / September 15, 2020 / Juan Monteverde , founder, and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Pfenex Inc. (NYSE American: PFNX ) relating to it...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately s...